Cancerous inhibitor of protein phosphatase 2A enhances chemoresistance of gastric cancer cells to oxaliplatin

Table 1 Association between the expression of cancerous inhibitor of protein phosphatase 2A and clinicopathological features in patients with gastric cancer

Prognostic variables	Number	Expression of CIP2A		χ2	P value
		Low	High
Sex				1.766	0.184
Male	71	27	44
Female	37	19	18
Age, yr				0.175	0.676
< 60	68	30	38
≥ 60	40	16	24
Tumor location				0.097	0.756
Proximal + middle	37	15	22
Distal	71	31	40
Histological grade				0.001	0.973
G1 + G2	26	11	15
G3	82	35	47
Tumor size in cm				5.975	0.015a
< 5	84	41	43
≥ 5	24	5	19
T stage				5.472	0.019a
T1–T2	36	21	15
T3–T4	72	25	47
N stage				12.428	0.000a
N0	47	29	18
N1–N3	61	17	44
TNM stage				5.168	0.023a
I + II	69	35	34
III + IV	39	11	28

^aP < 0.05.

CIP2A: Cancerous inhibitor of protein phosphatase 2A; G: Grade; N: Node; T: Tumor; TNM: Tumor Node Metastasis.